TGFB2 and neoplasm: However, it is still uncertain whether TGF-β2 antisense oligodeoxynucleotides (ASOs) can act as effective tumor vaccine adjuvants, and the specific mechanism by which TGF-β2 ASOs enhance antitumor immune responses is still elusive due to limited research findings.